Autolus Therapeutics's quarterly market cap
increased
from Sep. 2025 (€367.27 Mil) to Dec. 2025 (€431.15 Mil) but then
declined
from Dec. 2025 (€431.15 Mil) to Mar. 2026 (€295.42 Mil).
Autolus Therapeutics's annual market cap
declined
from Dec. 2023 (€1,027.20 Mil) to Dec. 2024 (€569.50 Mil) and
declined
from Dec. 2024 (€569.50 Mil) to Dec. 2025 (€431.15 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Autolus Therapeutics's Enterprise Value for Today is €254.99 Mil.
Autolus Therapeutics (FRA:6A3A) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Autolus Therapeutics Market Cap Related Terms
Autolus Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Autolus Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6A3A vs FBRX, SGMT, EDIT: Market Cap Comparison
For the Biotechnology subindustry, Autolus Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autolus Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Autolus Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Autolus Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autolus Therapeutics (FRA:6A3A) has a Market Cap of €385.90 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Autolus Therapeutics and its competitors. According to the industry distribution chart, Autolus Therapeutics ranks #444 out of 1423 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Autolus Therapeutics' Market Cap too high?
Autolus Therapeutics' current Market Cap is €385.90 Mil. Based on the distribution chart, Autolus Therapeutics ranks #444 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Autolus Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Market Cap compare to FBRX and SGMT?
According to the Biotechnology industry distribution chart, Autolus Therapeutics ranks #444 out of 1423 companies for Market Cap. This puts Autolus Therapeutics in the upper half of its industry. The industry median Market Cap is 121.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.30, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Autolus Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autolus Therapeutics's current Market Cap is €385.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €15.89, compared to a current price of €1.45 — trading 90.9% below its estimated fair value. The current Market Cap is €385.90 Mil. Autolus Therapeutics' overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Market Cap is €385.90 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?
Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued.
The current stock price of €1.45 is trading 90.9% below its estimated GF Value™ of €15.89.
GuruFocus considers Autolus Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:6A3A:
Market Cap: €385.90 Mil
GF Value™: €15.89 vs. price of €1.45 (90.9% below fair value)
No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
69GF Score
Get the complete analysis for FRA:6A3A
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6A3A has been successfully added to your 
